Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 2 · 50%Moderate 1 · 25%High 0 · 0%

Potent vs moderate‐potency topical corticosteroid

Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema

Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 192 participants
Low

Potent vs moderate‐potency topical corticosteroid

Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 541 participants
Low

Potent vs moderate‐potency topical corticosteroid

Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 99 participants
Very low

Potent vs moderate‐potency topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema

Potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with moderate‐potency topical corticosteroid (moderate certainty).

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
OR 1.33 [0.93, 1.89]
15 studies · 1173 participants
Moderate